Defining an Individualized Treatment Strategy for Metastatic Renal Cancer

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Treatment of metastatic renal cell carcinoma (mRCC) has evolved dramatically within the past 10 years with the advent of therapy targeting the angiogenesis and mammalian target of rapamycin (mTOR) pathways. These therapies rapidly supplanted immunotherapy as a first-line systemic treatment option. Response rates, however, continue to vary, largely due to mRCC's clinical and molecular heterogeneity. This article reviews current understanding of mRCC biology and available treatments, discusses novel biomarkers that improve prognostication and may be able to predict response, and integrates available literature on surgical and systemic therapies into an individualized strategy.

Original languageEnglish (US)
Pages (from-to)233-249
Number of pages17
JournalUrologic Clinics of North America
Issue number2
StatePublished - May 2012


  • Individual
  • Metastatic
  • Personalize
  • Renal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Defining an Individualized Treatment Strategy for Metastatic Renal Cancer'. Together they form a unique fingerprint.

Cite this